Chryselle Nazare, MD
Internal Medicine · Savannah, GANPI 1912167578
Payments from drug & device makers
Across 343 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$719
- Lilly USA, LLC$588
- AstraZeneca$511
- Astellas Pharma US Inc$419
- E.r. Squibb & Sons, L.L.C.$410
- Novartis$401
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,80099%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $719 |
| Lilly USA, LLC | 30 | $588 |
| AstraZeneca(2 entities) | 27 | $511 |
| Astellas Pharma US Inc | 16 | $419 |
| E.r. Squibb & Sons, L.L.C. | 27 | $410 |
| Novartis | 23 | $401 |
| Johnson & Johnson | 26 | $395 |
| AbbVie(2 entities) | 19 | $353 |
| GSK | 21 | $347 |
| Pfizer | 11 | $206 |
| Boehringer Ingelheim | 11 | $189 |
| Dexcom, Inc. | 11 | $184 |
| Idorsia Pharmaceuticals US Inc | 7 | $141 |
| Exact Sciences | 7 | $116 |
| Amgen | 6 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $97 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Merck | 5 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $62 |
| Harmony Biosciences LLC | 2 | $53 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Bausch Health US, LLC | 2 | $40 |
| Medtronic | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Abbott | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Corium, LLC | 1 | $26 |
| Verity Pharmaceuticals Inc. | 1 | $24 |
| Tris Pharma Inc | 1 | $22 |
| Axonics, Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $19 |
| IBSA Pharma Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
How this compares
$5,860 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 128 | $153,493 |
| OzempicSemaglutide | 83 | $152,850 |
| JardianceEmpagliflozin | 58 | $70,962 |
| TradjentaLinagliptin | 55 | $60,253 |
| RybelsusSemaglutide | 28 | $58,648 |
| EliquisApixaban | 58 | $47,885 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $44,940 |
| JanuviaSitagliptin Phosphate | 42 | $42,143 |
| MounjaroTirzepatide | 30 | $35,050 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $34,253 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 35 | $29,797 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $25,450 |
| LinzessLinaclotide | 15 | $20,968 |
| GemtesaVibegron | 16 | $18,826 |
| TrulicityDulaglutide | 13 | $18,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $719 | $211,499111 claims |
| AstraZenecaFarxiga, Symbicort | $511 | $162,686143 claims |
| Boehringer IngelheimJardiance, Tradjenta | $189 | $131,215113 claims |
| MerckJanuvia, Janumet Xr, Janumet | $72 | $81,72189 claims |
| Lilly USA, LLCMounjaro, Trulicity | $588 | $53,41843 claims |
| PfizerEliquis | $206 | $47,88558 claims |
| GSKTrelegy Ellipta | $347 | $44,94034 claims |
| AbbVieLinzess | $353 | $20,96815 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $76 | $18,82616 claims |
| Astellas Pharma US IncMyrbetriq | $419 | $17,46421 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $43 | $3,391243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Savannah
- Paul BradleySavannah$76.4M
- Thomas MoriaritySavannah$4.6M
- Nancy BackusSavannah$1.2M
- Robert RemlerSavannah$255K
- Jennifer WoehlerSavannah$207K
- Brooke HalpernSavannah$185K
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.